Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
about
Recent treatment advances and novel therapies in pancreas cancer: a review.Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.Pancreatic biomarkers: could they be the answer?Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.PharmGKB summary: gemcitabine pathwayIdentification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma.Drug metabolism and pancreatic cancer.New biomarkers and targets in pancreatic cancer and their application to treatment.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
P2860
Q33625168-61410B6F-2800-4E2C-919F-EFC6399F2744Q33684978-D7B35D4C-8A7E-457D-9E3F-BA1427E953C0Q33801371-86AA7D02-759E-47BC-B85D-9EDB8CE49EADQ33914197-34F6B99C-6A50-4890-ABBE-648F1E7B1561Q34435450-714F51D7-F7C8-4F2D-9E06-5EA8B4140310Q34644418-A614A98A-A6BA-4202-AC06-30B14C50A945Q35591895-26098543-BF0A-4C3A-BF38-161F523957CEQ37542844-7AA3600E-2407-499C-BAEF-5A726EDDB88BQ38021692-C741F521-0E5E-48E0-84B3-C56E5D7CE578Q38125770-699A6666-335B-4FC2-87D7-3F7C1AE8585BQ39283216-1ECF9A4C-FAAE-4C60-8A14-4FD6B6A24820Q40631094-CB5CC8B3-B198-450B-8AF6-708C3524584BQ47830761-F2CA4CF2-4B19-471F-BF23-D9141A8968EDQ50040885-F3AD19FA-5246-46FB-830C-F4DA0098B709Q52739894-CE815889-9126-4AE5-947F-901DFBFB5933
P2860
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@ast
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@en
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@nl
type
label
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@ast
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@en
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@nl
prefLabel
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@ast
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@en
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@nl
P2093
P2860
P356
P1433
P1476
Is there a role for the quanti ...... creatic ductal adenocarcinoma?
@en
P2093
Agnieszka K Witkiewicz
Benjamin E Leiby
Charles J Yeo
Edward Pequignot
Jonathan R Brody
Matias E Valsecchi
Susan J Littman
Thomas Holdbrook
P2860
P2888
P356
10.1186/1471-2407-12-104
P407
P577
2012-03-22T00:00:00Z
P5875
P6179
1007455327